Tudesq JJ - Search Results

1

Invasive Pulmonary Aspergillosis in Nonimmunocompromised Hosts.

Tudesq JJ, Peyrony O, Lemiale V, Azoulay E. Tudesq JJ, et al. Semin Respir Crit Care Med. 2019 Aug;40(4):540-547. doi: 10.1055/s-0039-1696968. Epub 2019 Oct 4. Semin Respir Crit Care Med. 2019. PMID: 31585479 Review.

2

Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study.

Lemiale V, Pons S, Mirouse A, Tudesq JJ, Hourmant Y, Mokart D, Pène F, Kouatchet A, Mayaux J, Nyunga M, Bruneel F, Meert AP, Borcoman E, Bisbal M, Legrand M, Benoit D, Azoulay E, Darmon M, Zafrani L. Lemiale V, et al. Among authors: tudesq jj. Crit Care Med. 2020 Jun;48(6):822-829. doi: 10.1097/CCM.0000000000004322. Crit Care Med. 2020. PMID: 32317596

3

Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy study.

Tudesq JJ, Valade S, Galicier L, Zafrani L, Boutboul D, de Bazelaire C, Munoz-Bongrand N, Canet E, Ardisson F, Lemiale V, Darmon M, Azoulay E, Mariotte E. Tudesq JJ, et al. Hematol Oncol. 2021 Feb;39(1):114-122. doi: 10.1002/hon.2819. Epub 2020 Nov 1. Hematol Oncol. 2021. PMID: 33099794

4

Impact of prone position in non-intubated spontaneously breathing patients admitted to the ICU for severe acute respiratory failure due to COVID-19.

Jouffroy R, Darmon M, Isnard F, Geri G, Beurton A, Fartoukh M, Tudesq JJ, Nemlaghi S, Demoule A, Azoulay E, Vieillard-Baron A. Jouffroy R, et al. Among authors: tudesq jj. J Crit Care. 2021 Aug;64:199-204. doi: 10.1016/j.jcrc.2021.04.014. Epub 2021 May 1. J Crit Care. 2021. PMID: 33990007 Free PMC article.

5

Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis.

Valade S, Joly BS, Veyradier A, Fadlallah J, Zafrani L, Lemiale V, Launois A, Stepanian A, Galicier L, Fieschi C, Mirouse A, Tudesq JJ, Lepretre AC, Azoulay E, Darmon M, Mariotte E. Valade S, et al. Among authors: tudesq jj. PLoS One. 2021 Aug 3;16(8):e0251216. doi: 10.1371/journal.pone.0251216. eCollection 2021. PLoS One. 2021. PMID: 34343182 Free PMC article. Clinical Trial.

6

Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect.

Saade A, Moratelli G, Dumas G, Mabrouki A, Tudesq JJ, Zafrani L, Azoulay E, Darmon M. Saade A, et al. Among authors: tudesq jj. Ann Intensive Care. 2021 May 25;11(1):83. doi: 10.1186/s13613-021-00873-x. Ann Intensive Care. 2021. PMID: 34036411 Free PMC article.

7

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.

Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Hermine O, et al. JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820. JAMA Intern Med. 2021. PMID: 33080017 Free PMC article. Clinical Trial.

8

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.

CORIMUNO-19 Collaborative group. CORIMUNO-19 Collaborative group. Lancet Respir Med. 2021 Mar;9(3):295-304. doi: 10.1016/S2213-2600(20)30556-7. Epub 2021 Jan 22. Lancet Respir Med. 2021. PMID: 33493450 Free PMC article. Clinical Trial.

9

Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology.

Prattes J, Wauters J, Giacobbe DR, Salmanton-García J, Maertens J, Bourgeois M, Reynders M, Rutsaert L, Van Regenmortel N, Lormans P, Feys S, Reisinger AC, Cornely OA, Lahmer T, Valerio M, Delhaes L, Jabeen K, Steinmann J, Chamula M, Bassetti M, Hatzl S, Rautemaa-Richardson R, Koehler P, Lagrou K, Hoenigl M; ECMM-CAPA Study Group. Prattes J, et al. Clin Microbiol Infect. 2022 Apr;28(4):580-587. doi: 10.1016/j.cmi.2021.08.014. Epub 2021 Aug 26. Clin Microbiol Infect. 2022. PMID: 34454093 Free PMC article.

10

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.

CORIMUNO-19 Collaborative group. CORIMUNO-19 Collaborative group. Lancet Rheumatol. 2022 Jan;4(1):e24-e32. doi: 10.1016/S2665-9913(21)00315-5. Epub 2021 Nov 17. Lancet Rheumatol. 2022. PMID: 34812424 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page